scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.OPHTHA.2016.09.025 |
P8608 | Fatcat ID | release_dmctxmbpwjg4xl7qv2ooxwoele |
P698 | PubMed publication ID | 28079022 |
P2093 | author name string | Jodi Luchs | |
Edward J Holland | |||
Aparna Raychaudhuri | |||
Joseph Tauber | |||
Kenneth Sall | |||
Kelly K Nichols | |||
Paul M Karpecki | |||
Amir Shojaei | |||
Monica Roy | |||
Mitchell A Jackson | |||
P433 | issue | 1 | |
P921 | main subject | phase III clinical trial | Q42824827 |
placebo-controlled trial | Q108853737 | ||
placebo | Q269829 | ||
eye disease | Q3041498 | ||
P304 | page(s) | 53-60 | |
P577 | publication date | 2016-10-27 | |
P1433 | published in | Ophthalmology | Q7098109 |
P1476 | title | Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3). | |
P478 | volume | 124 |
Q90615647 | A Review of Management Strategies for Nociceptive and Neuropathic Ocular Surface Pain |
Q92442286 | Advances in dry eye disease treatment |
Q47639135 | Dry eye syndrome: developments and lifitegrast in perspective |
Q36252489 | Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment |
Q64916636 | Effects of packaging design on sensory liking and willingness to purchase: A study using novel chocolate packaging. |
Q39069560 | Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease |
Q38608475 | Lifitegrast for the treatment of dry eye disease in adults |
Q33739879 | Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy |
Q93137705 | Lifitegrast: a novel drug for patients with dry eye disease |
Q64106425 | Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity |
Q47739620 | Neuropathic pain and dry eye. |
Q47268214 | Ocular Distribution and Pharmacokinetics of Lifitegrast in Pigmented Rabbits and Mass Balance in Beagle Dogs |
Q93341813 | Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Wo |
Q49261503 | Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial. |
Q90371647 | Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT |
Q52608828 | Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye. |
Q52661549 | Reflections on Dry Eye Syndrome Treatment: Therapeutic Role of Blood Products. |
Q58694745 | Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort |
Q92236526 | Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review |
Q90351231 | The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options |
Q48344821 | The Use of Topical Corticosteroids for Treatment of Dry Eye Syndrome. |
Q47424328 | Update in Current Diagnostics and Therapeutics of Dry Eye Disease. |
Q88350776 | n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease |
Search more.